The cellular immunotherapy of primary brain tumors
- PMID: 1448666
The cellular immunotherapy of primary brain tumors
Abstract
The use of adjuvant immunotherapy for the treatment of primary malignant brain tumors dates to studies performed in the 1960's and 1970's using non-specific immune stimulators. Although the theoretical designs have remained similar, recent advances in molecular biotechnology have produced a new group of recombinant cytokines, spawning a new generation of immunotherapy-based clinical trials. In contrast to other published Phase I/II studies, we have had highly encouraging preliminary results using lymphokine-activated killer (LAK) cells and recombinant human Interleukin-2 (rIL-2; Cetus, Emeryville, CA), when the patients' use of corticosteroids could be restricted while on study. Patients with recurrent grade 3/3 glioma received multiple cycles of autologous LAK cells and rIL-2, post-operatively, via an Ommaya reservoir implanted into the tumor cavity following re-operation. The overall median survival for 13 patients with grade 3/3 glioma has not yet been reached at 55 weeks following second surgery, [mean +/- SEM, 64.7 +/- 10.5 weeks], with 5 patients still alive. Three patients have had partial responses (PR) demonstrated by CT scanning. In addition, one patient with grade 2/3 glioma has had a complete response (CR), with the disappearance of all residual CT-documented enhancement and mass effect.
Similar articles
-
Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.Cancer Res. 1990 Jul 15;50(14):4338-43. Cancer Res. 1990. PMID: 2364388
-
Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.J Immunother. 2009 Nov-Dec;32(9):914-9. doi: 10.1097/CJI.0b013e3181b2910f. J Immunother. 2009. PMID: 19816190 Clinical Trial.
-
Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.Online J Curr Clin Trials. 1993 Dec 29;Doc No 111:[806 words; 5 paragraphs]. Online J Curr Clin Trials. 1993. PMID: 8305997 Clinical Trial. No abstract available.
-
[A history and prospect of adoptive immunotherapy against malignant glioma--past, now and future].No To Shinkei. 1992 Jul;44(7):605-13. No To Shinkei. 1992. PMID: 1419336 Review. Japanese. No abstract available.
-
[Cellular immunotherapy for malignant glioma].Nihon Rinsho. 2005 Sep;63 Suppl 9:557-62. Nihon Rinsho. 2005. PMID: 16201581 Review. Japanese. No abstract available.
Cited by
-
Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper.J Neurooncol. 2010 Apr;97(2):159-69. doi: 10.1007/s11060-009-0016-0. Epub 2009 Oct 4. J Neurooncol. 2010. PMID: 19802719 Free PMC article. Review.
-
Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors.J Neurooncol. 1994;19(2):161-8. doi: 10.1007/BF01306458. J Neurooncol. 1994. PMID: 7964992
-
Lymphokine activated killer cells from umbilical cord blood show higher antitumor effect against anaplastic astrocytoma cell line (U87) and medulloblastoma cell line (TE671) than lymphokine activated killer cells from peripheral blood.Childs Nerv Syst. 2004 Mar;20(3):154-62. doi: 10.1007/s00381-003-0898-7. Epub 2004 Feb 13. Childs Nerv Syst. 2004. PMID: 14968374
-
Activated monocytes kill malignant brain tumor cells in vitro.J Neurooncol. 1994;20(1):35-45. doi: 10.1007/BF01057959. J Neurooncol. 1994. PMID: 7807182
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials